Ibufenac

Summary

Ibufenac (CHEMBL341812) is an approved small-molecule non-steroidal anti-inflammatory drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 192.25 Da · C12H16O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL341812
Name	Ibufenac
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	15250
ChEBI	CHEBI:76158
Molecular formula	C12H16O2
Molecular weight	192.25
InChIKey	CYWFCPPBTWOZSF-UHFFFAOYSA-N

SMILES: CC(C)CC1=CC=C(C=C1)CC(=O)O

IUPAC name: 2-[4-(2-methylpropyl)phenyl]acetic acid

ChEBI definition: A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, hepatotoxic agent, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor.

Also known as: (p-isobutylphenyl)acetic acid, Dytransin, Ibufenac, Ibufenaco, NSC-99976, RD 11654, RD-11654, SID29216132, ibufenac, IBUFENAC, SID170465922

Patent coverage: 3,047 distinct patent families (11,975 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Prostaglandin G/H synthase 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q05769	5.26	IC50	5500	nM	CHEMBL_ACT_12055627

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).